Strategic conferences, research insights, and society management
Connecting experts. Advancing healthcare.
AUG 1
SAN FRANCISCO
Services
We provide end-to-end healthcare engagement and management services designed specifically for the medical and pharmaceutical ecosystem. Our expertise includes comprehensive conference management—from medical congress planning, venue selection, speaker coordination, abstract handling, registration systems, and exhibition management—to seamless execution of webinars and virtual events such as doctor webinars, CME education programs, and online conferences with virtual networking.
We also support medical societies through membership management, event planning, communication strategies, and digital presence development. In addition, our healthcare market research services deliver valuable doctor surveys, patient insights, pharma research, and market analytics. Complementing these services, we offer targeted event marketing solutions, including conference promotion and strategic email outreach to doctors, ensuring maximum engagement and impact across the healthcare community.
The Webinars
Up coming next
Update Hour
19 March
Once a month AI update meeting for Doctors Ai community members. Brainstrom your ideas & collaborate towards a better future in healthcare.
Update Hour
19 March
Once a month AI update meeting for Doctors Ai community members. Brainstrom your ideas & collaborate towards a better future in healthcare.
Docotors Ai
20 March 2026
Explore the landscape of artificial intellegence in healthcare with discussion on cutting-edge scientifi research and evidences. Share your own research and innovative on new Ai Research ideas.
01
05
178
Hour
SPEAKERS
PARTICIPANTS
The News
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by joint inflammation, structural damage, and associated skin manifestations of psoriasis. Despite the availability of several biologic and targeted therapies, many patients continue to experience persistent disease activity or treatment intolerance, highlighting the need for additional therapeutic options. Deucravacitinib (Sotyktu), an oral selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb, has now received approval from the U.S. Food and Drug Administration for the treatment of adults with active psoriatic arthritis. This approval represents the first TYK2 inhibitor authorized for this indication and introduces a novel mechanism targeting intracellular cytokine signaling pathways involved in immune-mediated inflammation.
